Atea shareholders elect three Class II directors, ratify KPMG, approve executive compensation

Atea Pharmaceuticals, Inc.

Bruno Lucidi, Polly Murphy, and Bruce Polsky elected as Class II directors to 2028 term.
Ratification of KPMG as independent auditor for FY2025 approved with 73.8M votes for.
Advisory (non-binding) approval of named executive officer compensation received 46.5M votes for.
Approximately 87.6% of outstanding shares represented at June 20, 2025 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.